Roche makes changes to corporate executive committee

Daniel O’Day becomes head of Roche Pharma and Roland Diggelmann head of Roche Diagnostics

Swiss pharmaceutical manufacturer Roche has appointed Daniel O’Day, currently chief operating officer (coo) of Roche Diagnostics, as coo of Roche Pharma, effective from 1 September. He will succeed Pascal Soriot, who becomes ceo of AstraZeneca on 1 October.

O’Day will be succeeded by Roland Diggelmann, currently head of the Asia-Pacific region within Roche Diagnostics, who has also been appointed as a new member of the executive committee by the board of directors.

O’Day began his career at Roche in 1987 in sales and marketing within the US Pharmaceuticals organisation. He later held various positions at Roche Pharma in Switzerland, Japan, and Denmark.

In 2006 O’Day joined Roche Diagnostics and became head of the Molecular Diagnostics business. On 1 January 2010 he was appointed coo for Roche’s global diagnostics business.

Roland Diggelmann

Roland Diggelmann

Before joining Roche in 2008, Diggelmann held various leading positions in sales and marketing in Europe and Asia-Pacific with the medical technology companies Sulzer Medica/Centerpulse and Zimmer. He was also responsible for the integration of Centerpulse’s Japanese business into Zimmer. At Roche Diagnostics, he has led the region Asia-Pacific since 2008 as member of the divisional leadership team.

You may also like

Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Regulatory

Roche's breast cancer combination therapy Itovebi bags FDA approval

Itovebi plus palbociclib and fulvestrant reduced the risk of disease progression or death significantly in patients
Finance

Lonza completes acquisition of large-scale biologics site in Vacaville (US) from Roche

Acquisition extends Lonza’s US Biologics footprint with a significant presence on the West Coast, complementing its existing global manufacturing network
Research & Development

Roche's antiviral Xofluza reduces flu transmission in Phase III trial

Topline results suggest that Xofluza could be used to reduce the transmission of seasonal influenza
Regulatory

Roche's cancer immunotherapy Tecentriq Hybreza bags FDA approval

The drug first and only subcutaneous PD-(L)1 inhibitor available for patients with certain types of lung, skin, liver and soft tissue cancers
Research & Development

Roche's multiple sclerosis drug fenebrutinib displays positive Phase II data

The drug was able to stop a majority of patients from relapsing, while also halting disability progression in the FENopta study
Regulatory

Roche receives approval for PiaSky to treat patients with PNH in Europe

The subcutaneous C5 inhibitor stops the patients from having to attend the clinic to receive IV infusions for PNH management
Subscribe now